This text is a result of machine translation.
In the half year, the 36billion yuan production expansion plan has been thrown away, and the competition in the stock market of Baijiu is fierce
Research
Consumer StaplesChina’s Food and Beverage Industry in Search of Methods to Shrink its Carbon Footprints
Cro plate fell, and Wuxi apptec fell nearly 10%
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Mar 31, 2021 11:38 AM
Capital group, an asset management institution, launched ETF products for the first time: buying Chinese stocks such as Guizhou Maotai, Yaoming biology and meituan